HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA ...
Generally the result of age- related decreases in androgen production, sebaceous hyperplasia is characterized by common asymptomatic papules. The condition occurs most frequently in healthy ...
(RTTNews) - Pulse Biosciences Inc.'s (PLSE) CellFX System has received Investigational Device Exemption approval from the FDA and a pivotal study evaluating this device in the treatment of sebaceous ...
Sebaceous hyperplasia is most common in middle-aged or older people, particularly those with fair skin who have had a lot sun exposure. There is currently no cure for sebaceous hyperplasia. Some ...
I have never seen anything in your column about sebaceous hyperplasia. I read that it is quite similar to acne and that a person could use an acne treatment to keep the condition in check. Could you ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...
This patient had sebaceous hyperplasia, a benign proliferation of the sebaceous gland that occurs in a periorbital location on patients of middle age or older. The condition is characterized by small, ...
The FDA has granted 510(k) clearance to Pulse Biosciences Inc's (NASDAQ: PLSE) CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with ...
Please provide your email address to receive an email when new articles are posted on . Pulse Biosciences has announced it received FDA 510(k) clearance for expanding the use of its CellFX System to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback